news
Blood cancer study yields disappointing results
19 July 2016 | By Niamh Louise Marriott
Gazyvaro did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with diffuse large B-cell lymphoma...
List view / Grid view
Gazyvaro (obinutuzumab)
news
EC approves Gazyvaro plus bendamustine in follicular lymphoma
The European Commission has approved Roche’s Gazyvaro (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance in people with follicular lymphoma.
news
Positive results from Phase III study of Gazyva in follicular lymphoma
27 May 2016 | By Victoria White, Digital Content Producer
Roche has announced positive results from the pivotal Phase III GALLIUM study.
news
NICE issues final approval for Gazyvaro in chronic lymphocytic leukaemia
From today, clinicians in England and Wales will be able to prescribe Roche's Gazyvaro for eligible patients with chronic lymphocytic leukaemia (CLL) on the NHS.
news
Gazyvaro stalls growth and spread of indolent non-Hodgkin’s lymphoma
1 June 2015 | By Victoria White
Results from a Phase III study show that Gazyvaro provided significant benefit for people with indolent non-Hodgkin’s lymphoma (NHL)...
news
Pivotal data for Roche medicines in lung and blood cancers to be presented at ASCO 2015
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
news
NICE says ‘yes’ to new blood cancer drug
11 March 2015 | By Roche
New option for patients as NICE accepts Gazyvaro® (obinutuzumab) for treatment of most common adult leukaemia...
news
Roche’s Phase III study of Gazyva/Gazyvaro showed significant benefit in refractory indolent non-Hodgkin’s lymphoma
4 February 2015 | By Roche
Roche announced positive results from the Phase III GADOLIN study, which evaluated treatment options for people with indolent non-Hodgkin’s lymphoma (iNHL) who are refractory to MabThera®/Rituxan® (rituximab) treatment...
news
Roche to present clinical data from six different medicines at ASH
9 December 2014 | By Roche
Presentations include data on Roche’s broad portfolio of hematology medicines as well as emerging investigational agents including ACE910 (RG6013) in hemophilia A...
news
SMC says ‘yes’ to new blood cancer drug
9 December 2014 | By Roche
Victory for Scottish NHS patients as SMC accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia...
news
NICE reverses decision on access to new blood cancer drug
2 December 2014 | By Roche
Victory for patients as NICE accepts Gazyvaro™ (obinutuzumab) for treatment of most common adult leukaemia1...
news
Roche’s Gazyvaro approved in Europe for patients with the most common type of leukemia
29 July 2014 | By Roche
Roche announced that the European Commission has approved Gazyvaro (obinutuzumab) in combination with chlorambucil chemotherapy...
news
CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia
23 May 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia...
news
Roche’s obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan in people with one of the most common forms of blood cancer
24 July 2013 | By Roche
Results from the phase III CLL11 study...
news
FDA grants Roche’s obinutuzumab (GA101) Priority Review for previously untreated chronic lymphocytic leukemia
3 July 2013 | By Roche
FDA decision on the GA101 BLA is expected by the end of 2013...
